| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/29/2006 | US20060141070 Notoginseng saponin intravenous injection and the method for preparing this injection |
| 06/29/2006 | US20060141059 Multi-dose; no conventional preservatives; also comprises borate/propylene glycol, borate/glycerol |
| 06/29/2006 | US20060141058 Methods and compositions for weight management and mood enhancement |
| 06/29/2006 | US20060141057 Methods of treatment of inflammatory diseases |
| 06/29/2006 | US20060141052 Drug microparticles |
| 06/29/2006 | US20060141051 Drug microparticles |
| 06/29/2006 | US20060141050 Drug microparticles |
| 06/29/2006 | US20060141049 Suspended in viscosity modifier (hyaluronic acid) and carrier; sustained release; treating macular edem |
| 06/29/2006 | US20060141047 Methods and compositions for delivery of catecholic butanes for treatment of obesity |
| 06/29/2006 | US20060141044 Pharmaceutical compositions based on diclofenac derivate |
| 06/29/2006 | US20060141043 Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides |
| 06/29/2006 | US20060141037 Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof |
| 06/29/2006 | US20060141036 HMG-CoA reductase inhibitor extended release formulation |
| 06/29/2006 | US20060141035 HMG-COA reductase inhibitor extended release formulation |
| 06/29/2006 | US20060141034 GABA analog prodrug sustained release oral dosage forms |
| 06/29/2006 | US20060141033 P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient |
| 06/29/2006 | US20060141032 Effervescent formulations comprising apomorphine |
| 06/29/2006 | US20060141030 Method and composition for stable and controlled delivery of (-)-hydroxycitric acid |
| 06/29/2006 | US20060141029 Methods and compositions for delivery of catecholic butanes for treatment of diseases |
| 06/29/2006 | US20060141028 Cyclosporin formulations |
| 06/29/2006 | US20060141027 Sublingual administration of non-steroidal anti-inflammatory pharmacological substances |
| 06/29/2006 | US20060141025 treating malignant, premalignant or benign tumor arising from or associated with a tissue or organ selected from breast, liver, stomach, pancreas, colorectal, colon and prostate, by administering tetra-O-methyl NDGA and a carrier |
| 06/29/2006 | US20060141024 Synergistic combination kit of alpha,beta-arteether, sulfadoxin and pyrimethamine for treatment of severe/multi-drug resistant cerebral malaria |
| 06/29/2006 | US20060141023 Pharmaceutical compositions containing abiguanide-glitazone combination |
| 06/29/2006 | US20060141022 Soft capsule preparation |
| 06/29/2006 | US20060141018 Hemostatic compositions and methods for controlling bleeding |
| 06/29/2006 | US20060141013 Lysine mixture and apparatus and method for administering lysine |
| 06/29/2006 | US20060141010 Coated preparations that contain at least one hydroformate |
| 06/29/2006 | US20060141007 Agent with a retarded release of substances |
| 06/29/2006 | US20060141006 Methods and apparatus for treatment of aneurysmal tissue |
| 06/29/2006 | US20060140991 Pharmaceutical preparations having an improved solubility |
| 06/29/2006 | US20060140990 Composition for topical treatment of mixed vaginal infections |
| 06/29/2006 | US20060140989 Pharmaceutical formulations |
| 06/29/2006 | US20060140988 Visco-supplement composition and methods |
| 06/29/2006 | US20060140986 Anesthetic composition for topical administration |
| 06/29/2006 | US20060140985 Lansoprazole formulations and related processes and methods |
| 06/29/2006 | US20060140962 Combination treatment of pancreatic cancer |
| 06/29/2006 | US20060140947 Administering decitabine and tyrosine kinase inhibitor such as epidermal growth factor receptor family (EGFR); cancer therapy; chronic myelogenous leukemia |
| 06/29/2006 | US20060140928 Use of heparinases to decrease inflammatory response |
| 06/29/2006 | US20060140925 Composition of biochemical compounds involved in bioenergy metabolism of cells and method of use |
| 06/29/2006 | US20060140924 Topical composition for application to perianal and/or labial areas of skin which helps prevent viscoelastic fluids, such as menses and feces, from attaching to skin and aids in reducing viscoelastic properties of fluid so that fluid can flow into absorbent articles |
| 06/29/2006 | US20060140912 Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients |
| 06/29/2006 | US20060140907 Central airway administration for systemic delivery of therapeutics |
| 06/29/2006 | US20060140906 Composition comprising cysteamine for improving immunity of animals |
| 06/29/2006 | US20060140904 Random alkylene oxide copolymers for medical and surgical utilities |
| 06/29/2006 | US20060140903 Diagnoses and treatment of disorders using an alternative glucose pathway |
| 06/29/2006 | US20060140876 Buccal cavity treatment composition and corresponding uses thereof |
| 06/29/2006 | US20060140874 Stable aerosol formulations of peptides and protein with non-cfc propellants |
| 06/29/2006 | US20060140873 Aerosol pharmaceutical compositions |
| 06/29/2006 | US20060140872 Novel signaling pathway for the production of inglammatory pain and neuropathy |
| 06/29/2006 | US20060140866 measuring the accuracy of NMDA injection into a mouse brain comprising co-injecting methylene blue |
| 06/29/2006 | US20060140857 Method of the administration of drugs with binding affinity for plasma protein and preparation to be used in the method |
| 06/29/2006 | US20060140816 Sterilization of beclomethasone drug particles for pulmonary delivery |
| 06/29/2006 | US20060140140 System and method for power management in mobile units |
| 06/29/2006 | US20060137684 Compositions and methods of treating irritation and kit therefor |
| 06/29/2006 | DE19950686B4 Multifunktionelle Spacer Multifunctional Spacer |
| 06/29/2006 | DE112004001368T5 Produkt Product |
| 06/29/2006 | DE102004062182A1 Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff Transdermal patch with progesterone A-specific ligands (PRASL) as active ingredient |
| 06/29/2006 | DE102004061503A1 New meta-substituted thiazolidinone compounds are polo-like kinase inhibitors useful to treat cancers, autoimmune-, cardiovascular-, infectious-, nephrological-, nephrological- and neurodegenerative-diseases |
| 06/29/2006 | DE102004061288A1 New 3-amino-pyrazolo(3,4b)pyridine derivatives are protein tyrosine kinases inhibitors useful e.g. for treating hyperproliferation of body cells, neurodegenerative disease, blood vessel disease and angiogenic disease |
| 06/29/2006 | DE102004060229A1 Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen New cyclic ureas as inhibitors of metalloproteases |
| 06/29/2006 | DE102004060041A1 Use of substituted cyclopropane acid derivative having dopamine receptor ligand activity to e.g. treat metabolic syndrome; reduce lipid in the plasma; lower free fatty acid in the plasma; and treat diabetic dyslipidemia |
| 06/29/2006 | DE10038110B4 Pharmazeutische Zusammensetzungen Pharmaceutical compositions |
| 06/29/2006 | CA2634499A1 Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
| 06/29/2006 | CA2595517A1 Drug carrier and drug carrier kit for inhibiting fibrosis |
| 06/29/2006 | CA2594602A1 8-aza-bicyclo (3.2.1) octane derivatives with an activity on chemokine ccr5 receptors |
| 06/29/2006 | CA2592474A1 Prostaglandin f2.alpha. derivative-containing product |
| 06/29/2006 | CA2592468A1 Sabcomeline alone or combined with a mood stabilising or antimanic agent to treat bipolar disorders |
| 06/29/2006 | CA2592467A1 Glycine transport inhibitors |
| 06/29/2006 | CA2592464A1 Tricyclic .delta.-opioid modulators |
| 06/29/2006 | CA2592462A1 Tricyclic delta-opioid modulators |
| 06/29/2006 | CA2592442A1 Pyridine compounds for the treatment of prostaglandin mediated diseases |
| 06/29/2006 | CA2592411A1 Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders |
| 06/29/2006 | CA2592407A1 Methods of treating pain |
| 06/29/2006 | CA2592388A1 Imidazo[4,5-c]pyridine compound and method of antiviral treatment |
| 06/29/2006 | CA2592382A1 Modulator |
| 06/29/2006 | CA2592378A1 3-cycloalkylcarbonyl indoles as cannabinoid receptor ligands |
| 06/29/2006 | CA2592207A1 Antifungal properties of various forms of sophorolipids |
| 06/29/2006 | CA2592201A1 Neuromedin s and the use thereof |
| 06/29/2006 | CA2592170A1 Glycine derivative and use thereof |
| 06/29/2006 | CA2592162A1 Therapeutic compounds isolated form calomeria amarnthoides |
| 06/29/2006 | CA2592158A1 Methods of modulating the activities of alpha7 nicotinic acetylcholine receptor |
| 06/29/2006 | CA2592121A1 Methods for use of oral care compositions containing free-b-ring flavonoid anti-oxidants |
| 06/29/2006 | CA2592119A1 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as janus kinase inhibitors |
| 06/29/2006 | CA2592099A1 Conserved hbv and hcv sequences useful for gene silencing |
| 06/29/2006 | CA2592086A1 Mixture of a vanilloid receptor agonist and a substance inhibiting nerve regeneration, use thereof for producing a painkiller, and method for applying said painkiller |
| 06/29/2006 | CA2592030A1 Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| 06/29/2006 | CA2592009A1 Quinoline derivative, its use, production and pharmaceutical agents containing the latter |
| 06/29/2006 | CA2592004A1 Use of thiazolidinone derivatives as antiangiogenic agents |
| 06/29/2006 | CA2592002A1 Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions |
| 06/29/2006 | CA2592001A1 Chroman derivatives and their use as 5-ht receptor ligands |
| 06/29/2006 | CA2591997A1 Compositions comprising an epothilone and production methods |
| 06/29/2006 | CA2591996A1 Compositions including iron |
| 06/29/2006 | CA2591983A1 Pharmaceutical compositions comprising amorphous benzimidazole compounds |
| 06/29/2006 | CA2591980A1 Indole derivatives with antitumor activity |
| 06/29/2006 | CA2591970A1 Polyethylene glycolated superoxide dismutase mimetics |
| 06/29/2006 | CA2591963A1 Tricyclic o-opioid modulators |
| 06/29/2006 | CA2591946A1 Substituted heterocyclic compounds and methods of use |
| 06/29/2006 | CA2591940A1 Azole derivatives with antimuscarinic activity |
| 06/29/2006 | CA2591922A1 G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |